» Articles » PMID: 34948278

Stimulation of Sulfonamides Antibacterial Drugs Activity As a Result of Complexation with Ru(III): Physicochemical and Biological Study

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2021 Dec 24
PMID 34948278
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Antibiotic resistance is a global problem, and one promising solution to overcome this issue is using metallodrugs, which are drugs containing metal ions and ligands. These complexes are superior to free ligands in various characteristics including anticancer properties and mechanism of action. The pharmacological potential of metallodrugs can be modulated by the appropriate selection of ligands and metal ions. A good example of proper coordination is the combination of sulfonamides (sulfamerazine, sulfathiazole) with a ruthenium(III) ion. This work aimed to confirm that the activity of sulfonamides antibacterial drugs is initiated and/or stimulated by their coordination to an Ru(III) ion. The study determined the structure, electrochemical profile, -DNA affinity, and antimicrobial as well as anticancer properties of the synthesized complexes. The results proved that Ru(III) complexes exhibited better biological properties than the free ligands.

Citing Articles

New Ni(II) and Pd(II) complexes bearing derived sulfa drug ligands: synthesis, characterization, DFT calculations, and in silico and in vitro biological activity studies.

Bourouai M, Si Larbi K, Bouchoucha A, Terrachet-Bouaziz S, Djebbar S Biometals. 2022; 36(1):153-188.

PMID: 36427181 DOI: 10.1007/s10534-022-00469-3.


Application of the SwitchSense Technique for the Study of Small Molecules' (Ethidium Bromide and Selected Sulfonamide Derivatives) Affinity to DNA in Real Time.

Ramotowska S, Spisz P, Brzeski J, Ciesielska A, Makowski M J Phys Chem B. 2022; 126(38):7238-7251.

PMID: 36106569 PMC: 9527753. DOI: 10.1021/acs.jpcb.2c03138.


-Naphthoyl Thiourea Derivatives: An Efficient Ultrasonic-Assisted Synthesis, Reaction, and Anticancer Evaluations.

Arafa W, Ghoneim A, Mourad A ACS Omega. 2022; 7(7):6210-6222.

PMID: 35224384 PMC: 8867804. DOI: 10.1021/acsomega.1c06718.

References
1.
Kenny R, Marmion C . Toward Multi-Targeted Platinum and Ruthenium Drugs-A New Paradigm in Cancer Drug Treatment Regimens?. Chem Rev. 2019; 119(2):1058-1137. DOI: 10.1021/acs.chemrev.8b00271. View

2.
Anthony E, Bolitho E, Bridgewater H, Carter O, Donnelly J, Imberti C . Metallodrugs are unique: opportunities and challenges of discovery and development. Chem Sci. 2021; 11(48):12888-12917. PMC: 8163330. DOI: 10.1039/d0sc04082g. View

3.
Munteanu A, Uivarosi V . Ruthenium Complexes in the Fight against Pathogenic Microorganisms. An Extensive Review. Pharmaceutics. 2021; 13(6). PMC: 8232020. DOI: 10.3390/pharmaceutics13060874. View

4.
Ebrahimi H, Hadi J, Almayah A, Bolandnazar Z, Swadi A, Ebrahimi A . Metal-based biologically active azoles and β-lactams derived from sulfa drugs. Bioorg Med Chem. 2016; 24(5):1121-31. DOI: 10.1016/j.bmc.2016.01.041. View

5.
Garza-Ortiz A, Maheswari P, Siegler M, Spek A, Reedijk J . Ruthenium(III) chloride complex with a tridentate bis(arylimino)pyridine ligand: synthesis, spectra, X-ray structure, 9-ethylguanine binding pattern, and in vitro cytotoxicity. Inorg Chem. 2008; 47(15):6964-73. DOI: 10.1021/ic8005579. View